Companies Eagle Pharmaceuticals
Eagle Pharmaceuticals (EGRX): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
Eagle Pharmaceuticals no longer files a proxy statement; its last pay data is FY2022.
CEO vs. named peers69th pct.Of 16 peer CEOs
CEO pay, last three years
- $9,469,433FY2020
- $6,471,521FY2021
- $10,520,577FY2022
CEO total pay was $10,520,577 in fiscal 2022, up from $6,471,521 in fiscal 2021.
FY2022: salary $848,940 · bonus $0 · stock awards $9,011,197 · option awards $0
Frequently asked questions
Who was the highest-paid executive at Eagle Pharmaceuticals in fiscal 2022?
As disclosed, Scott Tarriff (President, Chief Executive Officer, Director) was the highest-paid executive at Eagle Pharmaceuticals in fiscal 2022, with total compensation of $10,520,577.
How does Eagle Pharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, Scott Tarriff's total compensation ranked at the 69th percentile of Eagle Pharmaceuticals's disclosed peer group.
What is Eagle Pharmaceuticals's CEO-to-median employee pay ratio?
As disclosed, Eagle Pharmaceuticals's CEO-to-median employee pay ratio was 43:1.
How much does Eagle Pharmaceuticals spend in total on board compensation for fiscal 2022?
As disclosed, Eagle Pharmaceuticals reported total board compensation of $590,000 for fiscal 2022.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Scott Tarriff | $848,940 | $0 | $9,011,197 | $0 | $636,705 | $0 | $23,735 | $10,520,577 |
| President, Chief Executive Officer, Director | ||||||||
| Michael Moran | 277,692 | 0 | 2,310,029 | 0 | 0 | 0 | 20,604 | 2,608,325 |
| Former Chief Commercial Officer | ||||||||
| Brian Cahill | 394,908 | 0 | 1,787,283 | 0 | 177,840 | 0 | 33,316 | 2,493,347 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Scott Tarriff | $10,520,577 | $6,471,521 | $9,469,433 | ↑ +4,049,056 |
| Michael Moran | 2,608,325 | 1,857,933 | — | ↑ +750,392 |
| Brian Cahill | 2,493,347 | 1,855,611 | 1,814,328 | ↑ +637,736 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract, retain and motivate superior executive talent, reward achievement of performance goals that directly correlate to enhancement of stockholder value, and align executives' interests with those of stockholders through long-term incentives. A significant portion of target total direct compensation is structured as 'at-risk' pay tied to company performance and stockholder returns.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2022
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian Cahill | RSU | 2022-02-28 | — | — | 8,000 | — | $379,120 |
| Michael Moran | PSU | 2022-02-28 | 15,550 | 31,100 | — | 46,650 | 1,817,173 |
| Brian Cahill | PSU | 2022-02-28 | 12,050 | 24,100 | — | 36,150 | 1,408,163 |
| Michael Moran | RSU | 2022-02-28 | — | — | 10,400 | — | 492,856 |
| Scott Tarriff | RSU | 2022-02-28 | — | — | 34,800 | — | 1,649,172 |
| Scott Tarriff | PSU | 2022-02-28 | 52,250 | 104,500 | — | 209,000 | 7,362,025 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brian Cahill | $379,120 | $1,408,163 | $0 | 78.8% |
| Michael Moran | 492,856 | 1,817,173 | 0 | 78.7% |
| Scott Tarriff | 1,649,172 | 7,362,025 | 0 | 81.7% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brian Cahill | Option | 284 | 41.37 | — |
| Brian Cahill | RSU | 1,704 | — | 49,808 |
| Brian Cahill | RSU | 2,500 | — | 73,075 |
| Scott Tarriff | Option | 2,858 | 42.4 | — |
| Brian Cahill | RSU | 3,500 | — | 102,305 |
| Brian Cahill | Option | 3,521 | 59.79 | — |
| Brian Cahill | Option | 4,583 | 48.09 | — |
| Brian Cahill | RSU | 6,675 | — | 195,110 |
| Brian Cahill | PSU | 7,600 | — | 386,992 |
| Brian Cahill | RSU | 8,000 | — | 233,840 |
| Brian Cahill | PSU | 8,900 | — | 453,188 |
| Scott Tarriff | RSU | 15,325 | — | 447,950 |
| Brian Cahill | PSU | 24,100 | — | 704,443 |
| Scott Tarriff | PSU | 25,900 | — | 1,318,828 |
| Scott Tarriff | RSU | 29,150 | — | 852,055 |
| Scott Tarriff | RSU | 34,800 | — | 1,017,204 |
| Scott Tarriff | Option | 39,460 | 59.79 | — |
| Scott Tarriff | PSU | 60,400 | — | 3,075,568 |
| Scott Tarriff | PSU | 104,500 | — | 3,054,535 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael GravesIndependent · Board Chair · Audit · Nominating and Corporate Governance (Chair) | $160,000 | $0 | $231,026 | — | $0 | $391,026 |
| Steven RatoffIndependent · Audit (Chair) · Compensation | 100,000 | 0 | 231,026 | — | 0 | 331,026 |
| Robert GlenningIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance | 93,750 | 0 | 231,026 | — | 0 | 324,776 |
| Richard A. EdlinIndependent · Compensation · Nominating and Corporate Governance | 81,250 | 0 | 231,026 | — | 0 | 312,276 |
| Luciana BorioIndependent · Nominating and Corporate Governance · Strategic Clinical Development (Chair) | 77,500 | 0 | 231,026 | — | 0 | 308,526 |
| Jennifer K. SimpsonIndependent · Compensation · Nominating and Corporate Governance · Strategic Clinical Development | 77,500 | 0 | 231,026 | — | 0 | 308,526 |
| Scott TarriffEmployee director · Strategic Clinical Development | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $65,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,500 |
| Stock ownership guideline | 3x annual retainer |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $590,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $590,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Eagle Pharmaceuticals as a peer
Companies that benchmark against EGRX
3 companies name EGRX as a compensation peer
- Coherus Oncology, Inc.CHRSFY2025
- DYNAVAX TECHNOLOGIES CORPDVAXFY2024
- Evofem Biosciences, Inc.EVFMFY2024
- KYNTRA BIO, INC.FGENFY2025
Each company listed discloses EGRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EGRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2022
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Clovis OncologyCOLL Collegium PharmaceuticalPBYI Puma BiotechnologySUPN Supernus PharmaceuticalsAMPH Amphastar PharmaceuticalsAGEN AgenusLGND Ligand PharmaceuticalsNKTR Nektar TherapeuticsCPRX Catalyst PharmaceuticalsCORT Corcept TherapeuticsPCRX Pacira BioSciencesICPT Intercept PharmaceuticalsLCI Lannett Co.CHRS Coherus BioSciencesGBT Global Blood TherapeuticsVNDA Vanda Pharmaceuticals
Peer reciprocity
The companies Eagle Pharmaceuticals names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Supernus Pharmaceuticals | 2025 | Jack Khattar | $1,036,000 | $6,535,029 | $7,031,545 | $846,930 | $15,501,557 |
| 2 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 3 | Pacira BioSciences | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 4 | Ligand Pharmaceuticals | 2025 | Todd Davis | 724,500 | 5,520,493 | 4,441,120 | 764,400 | 11,472,095 |
| 5 | Eagle Pharmaceuticals | 2022 | Scott Tarriff | 848,940 | 9,011,197 | 0 | 636,705 | 10,520,577 |
| 6 | Amphastar Pharmaceuticals | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 7 | Catalyst Pharmaceuticals | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 8 | Nektar Therapeutics | 2025 | Howard Robin | 1,106,282 | 942,081 | 2,986,535 | 1,106,282 | 6,256,954 |
| 9 | Intercept Pharmaceuticals | 2022 | Jerome Durso | 714,813 | 2,547,438 | 535,540 | 634,552 | 4,455,463 |
| 10 | Vanda Pharmaceuticals | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 11 | Puma Biotechnology | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 12 | Coherus BioSciences | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 13 | Collegium Pharmaceutical | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
| 14 | Agenus | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
| — | Lannett Co. | — | — | — | — | — | — | not in coverage universe |
| — | Global Blood Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Eagle Pharmaceuticals | 75% | PSU 75 · RSU 25 | Yes — Total Shareholder Return (TSR) relative to S&P 600 Biotech Select Index (rTSR) | Compensia |
| Agenus | 125% | Options 100 | not disclosed | Aon Radford |
| Amphastar Pharmaceuticals | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| Catalyst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Coherus BioSciences | not disclosed | Option 100 | not disclosed | Aon |
| Collegium Pharmaceutical | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Global Blood Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Intercept Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon plc's Rewards Solution practice (Radford) |
| Lannett Co. | not disclosed | not disclosed | not disclosed | not disclosed |
| Ligand Pharmaceuticals | 150% | not disclosed | No | Aon |
| Nektar Therapeutics | 100% | not disclosed | No | Aon |
| Pacira BioSciences | 90% | RSU 80 · PSU 20 | No | Aon |
| Puma Biotechnology | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Supernus Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Vanda Pharmaceuticals | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 43 : 1 |
|---|---|
| CEO total compensation | $10,520,577 |
| Median employee compensation | $245,274 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Scott Tarriff | Director | 2023-10-02 | D | 9,511 | $15 | $144,853 | Common | Form 4 ↗ |
| Scott Tarriff | Director | 2023-10-03 | D | 710 | 15 | 10,728 | Common | Form 4 ↗ |
| Scott Tarriff | Director | 2023-10-03 | D | 10,024 | 14 | 144,446 | Common | Form 4 ↗ |
| Michael Graves | Director | 2023-10-27 | D | 9,360 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Graves | Director | 2023-10-27 | A | 9,360 | 5 | 46,238 | Common | Form 4 ↗ |
| Scott Tarriff | Director | 2023-11-01 | D | 10,925 | 14 | 150,984 | Common | Form 4 ↗ |
| Scott Tarriff | Director | 2023-11-02 | D | 10,694 | 14 | 148,326 | Common | Form 4 ↗ |
| Brian Cahill | Chief Financial Officer | 2023-12-18 | D | 452 | 5 | 2,152 | Common | Form 4 ↗ |
| Michael Graves | Director | 2023-12-21 | A | 293,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Tarriff | Greater-than-10% holder | 2024-01-05 | D | 4,322 | 5 | 22,172 | Common | Form 4 ↗ |
| Brian Cahill | Chief Financial Officer | 2024-01-05 | D | 735 | 5 | 3,771 | Common | Form 4 ↗ |
| Brian Cahill | Chief Financial Officer | 2024-02-02 | D | 934 | 6 | 5,464 | Common | Form 4 ↗ |
| Brian Cahill | Chief Financial Officer | 2024-02-27 | D | 1,589 | 6 | 10,233 | Common | Form 4 ↗ |
| Scott Tarriff | Greater-than-10% holder | 2024-02-27 | A | 12,950 | — | — | Common | Form 4 ↗ |
| Scott Tarriff | Greater-than-10% holder | 2024-02-27 | D | 3,154 | 6 | 20,312 | Common | Form 4 ↗ |
| Brian Cahill | Chief Financial Officer | 2024-02-27 | A | 3,800 | 0 | 0 | Common | Form 4 ↗ |
| Scott Tarriff | Greater-than-10% holder | 2024-02-28 | D | 2,119 | 6 | 13,286 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (52 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Scott Tarriff. DEF 14A, filed 2023-05-01. Section “Executive Compensation”. As printed: 10,520,577. View filing ↗
- Section 01, Michael Moran. DEF 14A, filed 2023-05-01. Section “Executive Compensation”. As printed: 2,608,325. View filing ↗
- Section 01, Brian Cahill. DEF 14A, filed 2023-05-01. Section “Executive Compensation”. As printed: 2,493,347. View filing ↗
- Section 03, Brian Cahill RSU. DEF 14A, filed 2023-05-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Moran PSU. DEF 14A, filed 2023-05-01. Section “Grants of Plan-Based Awards for Fiscal Year 2022 Table” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Cahill PSU. DEF 14A, filed 2023-05-01. Section “Grants of Plan-Based Awards for Fiscal Year 2022 Table” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Moran RSU. DEF 14A, filed 2023-05-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Tarriff RSU. DEF 14A, filed 2023-05-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Tarriff PSU. DEF 14A, filed 2023-05-01. Section “Grants of Plan-Based Awards for Fiscal Year 2022 Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2023-05-01. Section “CEO Pay Ratio”. As printed: 43 : 1. View filing ↗
- Section 08, Michael Graves. DEF 14A, filed 2023-05-01. Section “Director Compensation”. As printed: 391,026. View filing ↗
- Section 08, Steven Ratoff. DEF 14A, filed 2023-05-01. Section “Director Compensation”. As printed: 331,026. View filing ↗
- Section 08, Robert Glenning. DEF 14A, filed 2023-05-01. Section “Director Compensation”. As printed: 324,776. View filing ↗
- Section 08, Richard A. Edlin. DEF 14A, filed 2023-05-01. Section “Director Compensation”. As printed: 312,276. View filing ↗
- Section 08, Luciana Borio. DEF 14A, filed 2023-05-01. Section “Director Compensation”. As printed: 308,526. View filing ↗
- Section 08, Jennifer K. Simpson. DEF 14A, filed 2023-05-01. Section “Director Compensation”. As printed: 308,526. View filing ↗
- Section 08, Scott Tarriff. DEF 14A, filed 2023-05-01. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Scott Tarriff 2023-10-02. Form 4, filed 2023-10-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Tarriff 2023-10-03. Form 4, filed 2023-10-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Tarriff 2023-10-03. Form 4, filed 2023-10-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Graves 2023-10-27. Form 4, filed 2023-10-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Graves 2023-10-27. Form 4, filed 2023-10-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Tarriff 2023-11-01. Form 4, filed 2023-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Tarriff 2023-11-02. Form 4, filed 2023-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Cahill 2023-12-18. Form 4, filed 2023-12-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Graves 2023-12-21. Form 4, filed 2023-12-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Tarriff 2024-01-05. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Cahill 2024-01-05. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Cahill 2024-02-02. Form 4, filed 2024-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Cahill 2024-02-27. Form 4, filed 2024-02-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Tarriff 2024-02-27. Form 4, filed 2024-02-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Tarriff 2024-02-27. Form 4, filed 2024-02-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Cahill 2024-02-27. Form 4, filed 2024-02-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Tarriff 2024-02-28. Form 4, filed 2024-03-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 590,000 + equity 0 + all other 0 = 590,000, summed across the director compensation table rows.
- Supernus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. View filing ↗
- Corcept Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. View filing ↗
- Pacira BioSciences, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. View filing ↗
- Ligand Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Ligand Pharmaceuticals's own proxy. As printed: 11,472,095. View filing ↗
- Eagle Pharmaceuticals (subject), Section 10b CEO total. DEF 14A, filed 2023-05-01. CEO total compensation as printed in Eagle Pharmaceuticals's own proxy. As printed: 10,520,577. View filing ↗
- Amphastar Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Amphastar Pharmaceuticals's own proxy. As printed: 8,309,350. View filing ↗
- Catalyst Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. View filing ↗
- Nektar Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Nektar Therapeutics's own proxy. As printed: 6,256,954. View filing ↗
- Intercept Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2023-05-01. CEO total compensation as printed in Intercept Pharmaceuticals's own proxy. As printed: 4,455,463. View filing ↗
- Vanda Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals's own proxy. As printed: 3,851,468. View filing ↗
- Puma Biotechnology, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology's own proxy. As printed: 3,062,337. View filing ↗
- Coherus BioSciences, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences's own proxy. As printed: 2,736,874. View filing ↗
- Collegium Pharmaceutical, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceutical's own proxy. As printed: 1,715,846. View filing ↗
- Agenus, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus's own proxy. As printed: 1,350,325. View filing ↗
- Section 10a, Coherus BioSciences reciprocity. DEF 14A. Coherus BioSciences names Eagle Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗